The global market for arthroscopy products and sports medicine implants is expected to reach $6.3bn by 2025, a CAGR of 1.9% from $5.7bn in 2020. The growth is driven partly by rising arthroscopy procedure volumes, expanding indications for joint repair, and patient preference for minimally invasive procedures. COVID-19 and downward pressures on device prices are among the growth barriers.  

In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam. 

The US FDA says it has received more than 450 Medical Device Reports since 2017 that describe patient infections following use of reprocessed cystoscopes, ureteroscopes and cystourethroscopes. Three deaths were reported by Olympus Corp.

Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.